The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
Open accessAbstract
The prognostic value of FoxP3(+) regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3(+) Treg across different types of cancer and to investigate factors associated with variations in this effect. PubMed, Embase, Cochrane CENTRAL, and Scopus were searched to identify eligible studies. In total, we analyzed 76 articles encompassing 17 types of cancer, and including 15,512 cancer cases. The overall pooled analysis including all types of cancer suggested FoxP3(+)Tregs had a significant negative effect on overall survival (OS) (OR 1.46, P < 0.001), but the prognostic effect varied greatly according to tumor site. High FoxP3(+) Tregs infiltration was significantly associated with shorter OS in the majority of solid tumors studied, including cervical, renal, melanomas, and breast cancers, et al; whereas, FoxP3(+) Tregs were associated with improved survival in colorectal, head and neck, and oesophageal cancers. The stratified analysis suggested the molecular subtype and tumor stage significantly influenced the prognostic value of FoxP3(+) Tregs in certain types of cancer. In conclusion, our meta-analysis suggests that the prognostic role of FoxP3(+) Tregs was highly influenced by tumor site, and was also correlated with the molecular subtype and tumor stage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Regulatory T Cells and Human Disease
Sakaguchi, S., Mikami, N., Wing, J. B., Tanaka, A., Ichiyama, K., & Ohkura, N. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041717 · Cited by 1,120
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment
Harjunpää, H., Llort Asens, M., Guenther, C., & Fagerholm, S. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01078 · Cited by 764
The future of cancer immunotherapy: microenvironment-targeting combinations
Murciano-Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 749
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
Binnewies, M., Mujal, A. M., Pollack, J. L., Combes, A. J., Hardison, E. A., Barry, K. C., Tsui, J., Ruhland, M. K., Kersten, K., Abushawish, M. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.005 · Cited by 629
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Tay, C., Tanaka, A., & Sakaguchi, S. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.014 · Cited by 580
Chaudhary, B., & Elkord, E. (2016) · Vaccines · doi:10.3390/vaccines4030028 · Cited by 511
Targeting Treg cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2019) · European Journal of Immunology · doi:10.1002/eji.201847659 · Cited by 476
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468
Chan, J. M., Quintanal-Villalonga, Á., Gao, V. R., Xie, Y., Allaj, V., Chaudhary, O., Masilionis, I., Egger, J., Chow, A., Walle, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.008 · Cited by 434
Kumar, M. P., Du, J., Lagoudas, G., Jiao, Y., Sawyer, A., Drummond, D. C., Lauffenburger, D. A., & Raue, A. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.047 · Cited by 421
Arce Vargas, F., Furness, A. J. S., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M. H., Miranda Rota, E., Dahan, R., Georgiou, A., Sledzinska, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.013 · Cited by 418
Jang, J.-E., Hajdu, C. H., Liot, C., Miller, G., Dustin, M. L., & Bar-Sagi, D. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.062 · Cited by 372
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Lim, C. J., Lee, Y. H., Pan, L., Lai, L., Chua, C., Wasser, M., Lim, T. K. H., Yeong, J., Toh, H. C., Lee, S. Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316510 · Cited by 357
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
Saleh, R., & Elkord, E. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.022 · Cited by 352
de Ruiter, E. J., Ooft, M. L., Devriese, L. A., & Willems, S. M. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356148 · Cited by 340
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., & Li, Y. (2021) · Cancers · doi:10.3390/cancers13061440 · Cited by 303
Regulatory T cells in the treatment of disease
Sharabi, A., Tsokos, M. G., Ding, Y., Malek, T. R., Klatzmann, D., & Tsokos, G. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.148 · Cited by 297
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
Idos, G. E., Kwok, J., Bonthala, N., Kysh, L., Gruber, S. B., & Qu, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-60255-4 · Cited by 291
Estimation of immune cell content in tumour tissue using single-cell RNA-seq data
Schelker, M., Feau, S., Du, J., Ranu, N., Klipp, E., MacBeath, G., Schoeberl, B., & Raue, A. (2017) · Nature Communications · doi:10.1038/s41467-017-02289-3 · Cited by 285
Fu, Q., Chen, N., Ge, C., Li, R., Li, Z., Zeng, B., Li, C., Wang, Y., Xue, Y., Song, X., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593806 · Cited by 274
T cell senescence and CAR-T cell exhaustion in hematological malignancies
Kasakovski, D., Xu, L., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0629-x · Cited by 272
Moreno Ayala, M. A., Campbell, T. F., Zhang, C., Dahan, N., Bockman, A., Prakash, V., Feng, L., Sher, T., & DuPage, M. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.003 · Cited by 241
Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812186116 · Cited by 205
Van Damme, H., Dombrecht, B., Kiss, M., Roose, H., Allen, E., Van Overmeire, E., Kancheva, D., Martens, L., Murgaski, A., Bardet, P. M. R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001749 · Cited by 205
Fiber Intake and Survival After Colorectal Cancer Diagnosis
Song, M., Wu, K., Meyerhardt, J. A., Ogino, S., Wang, M., Fuchs, C. S., Giovannucci, E. L., & Chan, A. T. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3684 · Cited by 197
Cancer Vaccines, Adjuvants, and Delivery Systems
Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200
Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195
Kumar, P., Saini, S., & Prabhakar, B. S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.01.006 · Cited by 117
Integrin-Mediated TGFβ Activation Modulates the Tumour Microenvironment
Brown, N. F., & Marshall, J. F. (2019) · Cancers · doi:10.3390/cancers11091221 · Cited by 116
Gut microbiota-mediated immunomodulation in tumor
Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01983-x · Cited by 112
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance
van Gulijk, M., van Krimpen, A., Schetters, S., Eterman, M., van Elsas, M., Mankor, J., Klaase, L., de Bruijn, M., van Nimwegen, M., van Tienhoven, T., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abn6173 · Cited by 110
Cancer-associated adipocytes as immunomodulators in cancer
Wu, Q., Li, B., Li, J., Sun, S., Yuan, J., & Sun, S. (2021) · Biomarker Research · doi:10.1186/s40364-020-00257-6 · Cited by 105
Whittle, J. R., Vaillant, F., Surgenor, E., Policheni, A. N., Giner, G., Capaldo, B. D., Chen, H.-R., Liu, H. K., Dekkers, J. F., Sachs, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1872 · Cited by 102
Echarti, A., Hecht, M., Büttner-Herold, M., Haderlein, M., Hartmann, A., Fietkau, R., & Distel, L. (2019) · Cancers · doi:10.3390/cancers11091398 · Cited by 87
Woods, D. M., Ramakrishnan, R., Laino, A. S., Berglund, A., Walton, K., Betts, B. C., & Weber, J. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1100 · Cited by 66
Obradovic, A., Ager, C., Turunen, M., Nirschl, T., Khosravi-Maharlooei, M., Iuga, A., Jackson, C. M., Yegnasubramanian, S., Tomassoni, L., Fernandez, E. C., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.04.003 · Cited by 66
Lee, J. A., Yoo, S.-Y., Oh, H. J., Jeong, S., Cho, N.-Y., Kang, G. H., & Kim, J. H. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02657-x · Cited by 61
Koll, F. J., Banek, S., Kluth, L., Köllermann, J., Bankov, K., Chun, F. K.-H., Wild, P. J., Weigert, A., & Reis, H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03949-3 · Cited by 47
Posselt, R., Erlenbach-Wünsch, K., Haas, M., Jeßberger, J., Büttner-Herold, M., Haderlein, M., Hecht, M., Hartmann, A., Fietkau, R., & Distel, L. V. (2016) · Oncotarget · doi:10.18632/oncotarget.11039 · Cited by 38
Integrated BATF transcriptional network regulates suppressive intratumoral regulatory T cells
Shan, F., Cillo, A. R., Cardello, C., Yuan, D. Y., Kunning, S. R., Cui, J., Lampenfeld, C., Williams, A. M., McDonough, A. P., Pennathur, A., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adf6717 · Cited by 38
Cho, J. H., & Lim, Y. C. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105084 · Cited by 27
(2022) · PubMed Central · Cited by 26
A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer
Brouwer, T., Ijsselsteijn, M., Oosting, J., Ruano, D., van der Ploeg, M., Dijk, F., Bonsing, B., Fariña, A., Morreau, H., Vahrmeijer, A., et al. (2022) · Cancers · doi:10.3390/cancers14163862 · Cited by 24
Li, Z., Wang, H., Zeng, Q., Yan, J., Hu, Y., Li, H., & Yu, Z. (2020) · Cancer Medicine · doi:10.1002/cam4.2611 · Cited by 20
Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells
Vidana Gamage, H. E., Albright, S. T., Smith, A. J., Farmer, R., Shahoei, S. H., Wang, Y., Fink, E. C., Jacquin, E., Weisser, E., Bautista, R. O., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217086 · Cited by 13
Huang, H., Cai, Y., Hong, X., Gao, W., Tang, J., Zhang, S., & Xu, Z. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.948734 · Cited by 6
Metadata
- Authors
- Shang, B., Liu, Y., Jiang, S.-J., & Liu, Y.
- Affiliations
- Shandong University (CN)
- Corresponding author
- Liu, Yi
- Venue
- Scientific Reports
- Published
- 2015-10-14
- Volume
- 5
- Issue
- 1
- Pages
- 15179-15179
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4604472
- OpenAlex
- W2419439766
- Cited by
- 985
- References
- 51
- Citations by year
- 2026: 51 · 2025: 84 · 2024: 101 · 2023: 94 · 2022: 148 · 2021: 139 · 2020: 118 · 2019: 91 · 2018: 87 · 2017: 47 · 2016: 24 · 2015: 1
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81301790)
- Natural Science Foundation of Shandong Province
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- Foxp3+ regulatory T cells, tumor-infiltrating lymphocytes, prognostic factors, overall survival, cancer, tumor location, molecular subtypes, tumor stage, solid tumors, cervical cancer, kidney cancer, melanoma, breast cancer, colorectal cancer, head and neck cancer, esophageal cancer
- MeSH terms
- Female, Humans, Male, Neoplasms, Prognosis, Sensitivity and Specificity, Biomarkers, Tumor, Reproducibility of Results, Prevalence, Survival Rate, Risk Assessment, T-Lymphocytes, Regulatory, Forkhead Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


